Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (20663)	7/28/2006 12:21:04 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 52153

I 'm familiar with Paion. I admire the Soehngens for having had the cojones to build a stroke company when almost all pharma firms were running the other way. The ultimate Pharma contrarians. Both Paion's DSPA and NTI's Viprinex have had bleeding problems in the past--it does look like Paion has been able to change the regimen to avoid that, and perhaps NTI has as well. Paion was particularly smart to use imaging to make sure there was a penumbra to be salvaged, a real advantage in their trial, which NTI is not doing. << Desmoteplase(plasminogen activator) and Enecadin(neuroprotectant) combination which is reco by intl stroke experts. Smart choice which RNVS doesn't have> I'm not sure I follow that....Enecadin is in Phase IIa, and until it shows human proof of principle, it remains in that chorus line of so many stroke drugs which have done so much....for occluded rodents....Will combining sodium and calcium channel blockage 'en suite' work for humans? Could be. Paion would be in great shape IF DSPA is approved and....Enecadin follows suit in 2012-13, they would own the best cocktail for stroke.... But any neuroprotectant can be combined with a thrombolytic, so in the meantime, IF NXY-059 passes muster, it will be often be given with tPA (indeed, it may expand the usability of tPA) for now, with DSPA and/or Viprinex later.... Harry NeuroInvestment